CPChrysanthi Papagiannaki

Chrysanthi Papagiannaki

*This is an algorithmically generated author record based on publicly available information.

Chrysanthi Papagiannaki has a total of 563 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stent-assisted coiling with LVIS Evo and HydroCoil embolic system: 1-year results of the SEALANT study

    by Jonathan Downer, Omer F Eker, Roberto Riva, Ansgar Berlis, Antonio Pitrone, Paul Stracke, Illario Tancredi, Charbel Mounayer, Chrysanthi Papagiannaki, Arun Chandran, et al.

    Background: More high-quality evidence for stent-assisted coiling (SAC) of cerebral aneurysms is needed. Randomized controlled trials have shown lower recurrence with the HydroCoil Embolic System (HES) compared with bare platinum coils, and self-adjudicated LVIS Evo SAC studies have demonstrated favorable safety and technical success. The objective of the SEALANT study is to investigate the safety and effectiveness of this device combination. Methods: SEALANT is an open-label, prospective, single-arm, multicenter study including patients with aneurysms up to a maximum size of 12 mm. The primary effectiveness endpoint was complete occlusion on digital subtraction angiography (DSA), and the primary safety endpoint was major ipsilateral stroke or neurological death. Adverse events and imaging were independently adjudicated. Results: 206 patients were enrolled; 193 had follow-up imaging for outcome assessment; and 164 satisfied all criteria, were treated with both study devices (including ≥90% HES), and had DSA follow-up. The participants’ mean age was 56.8±11.6 years; 65% were female. Of 212 aneurysms, 86.3% were bifurcation and 13.2% sidewall; 25.0% were previously treated and 17.9% previously ruptured; 89.6% were anterior circulation, 34.0% at the anterior communicating artery, and 30.7% at the middle cerebral artery; and 84.9% were wide-necked (neck ≥4 mm or dome/neck ratio <2). The primary effectiveness endpoint of complete occlusion was achieved in 82.1% (95% CI 76.4% to 87.9%) of aneurysms. 2.4% (95% CI 0.3% to 4.5%) of patients met the primary safety endpoint of major ipsilateral stroke or neurological death. The primary safety endpoint was significantly associated with baseline modified Rankin Scale and history of previous stroke. Conclusion: 1-year SEALANT results confirm the safety and effectiveness of SAC using LVIS Evo and HES. Trial registration number: NCT04999423 .

  • Open Access

    SQUID embolization for cerebral AVMs: 1-year safety and efficacy results from the CHOICE prospective multicenter study

    by Laurent Spelle, Gyula Gal, Xavier Barreau, Emmanuel Houdart, Markus A Möhlenbruch, Jean Christophe Gentric, Chrisanthi Papagiannaki, Michel Piotin, Luc Defreyne, Denis Trystram, et al.

    Background: Most patients with brain arteriovenous malformations (bAVMs) present with or eventually develop symptoms, while facing a persistent risk of rupture. Management remains challenging, and treatment practices continue to evolve. In this study, the safety and efficacy of embolization with the SQUID (BALT Group, Gland,Switzerland) embolic agent, used either as a standalone therapy or in combination with other modalities, were assessed. Methods: CHOICE is a prospective, observational, multicenter study conducted at 21 mainly European centers. Adults with previously untreated bAVMs were treated with SQUID, either as embolization alone or before neurosurgery or radiosurgery. The primary endpoint was SQUID- or procedure-related morbidity–mortality, at 3–6 months after last embolization or before further therapy. Secondary endpoints included bAVM occlusion at 3–6 months post-last embolization and safety at 12 months. Results: Among the 109 patients included (46.3±15 years, 50.5% male), 80.7% underwent embolization alone and 19.3% had further therapy. Most bAVMs were Spetzler–Martin grade I–II (67%) and <3 cm in diameter (78.9%). Morbidity-mortality related to SQUID and/or procedure at 3–6 months were 11% and 0% respectively, including 6.4% SQUID-related morbidity. At 12 months, these rates were 7.8% and 0% respectively, including 4.9% of SQUID-related morbidity. Complete bAVM occlusion at 3–6 months post-last embolization was achieved in 63.2% in embolization alone patients and 19.0% in patients with embolization before further therapy. The overall complete occlusion rate was 53.6%. Conclusion: CHOICE study results suggest good safety and efficacy of SQUID as a standalone treatment or in association with surgical treatment. Trial registration number: NCT03413852 .

  • Effect of antiangiogenic administration on arteriovenous malformations

    by Chrysanthi Papagiannaki

    Effet des antiangiogéniques sur les malformations artério-veineuses cérébrales: Les Malformations Artérioveineuses sont des lésions vasculaires évolutives. Elles peuvent avoir des conséquences neurologiques lourdes liées au risque hémorragique élevé qui est leur mode de révélation le plus fréquent. Le développement de meilleurs outils d’imagerie a beaucoup amélioré le diagnostic de ces lésions et a permis une meilleure compréhension de leur interaction avec le tissu cérébral. Néanmoins, Leur 4eme dimension et leur évolution restent encore obscures.Par ailleurs, les traitements actuels (embolisation, microchirurgie, chirurgie stéréotaxique) sont associés à des risques de morbidité et mortalité importants.Pour ces raisons, nous avons travaillé sur un traitement potentiel peu invasif: des agents antiangiogéniques. Un modèle porcin simplifié a été élaboré consistant en l’occlusion unilatérale de l’artère carotide primitive et externe par voie endovasculaire. Ce modèle a présenté des preuves d’angiogénèse et des modifications anatomopathologiques proches de celles des MAVc humaines. Le Bevacizumab, un anticorps monoclonal pour le VEGF, a été administré in situ sur ce modèle. Les résultats ont montré que l’agent antiangiogénique altère l’angiogénèse sur les specimens histologiques. L’épaisseur de la paroi des vaissaux a été stabilisée après l’injection de Bevacizumab mais le volume des retia est demeuré identique montrant que le volume dépend de l’angiogénèse mais probablement également du flux

  • Acute Carotid Stenting for Tandem Lesions in Patients Randomized to Endovascular Treatment With or Without Thrombolysis: Results From the IRIS Individual Participant Data Meta-Analysis

    by Fabiano Cavalcante, Kilian M. Treurniet, Johannes Kaesmacher, Manon Kappelhof, Roman Rohner, Pengfei Yang, Jianmin Liu, Kentaro Suzuki, Bernard Yan, Theodora van Elk, et al.

    BACKGROUND: Equipoise persists whether patients with stroke with carotid tandem lesions undergoing endovascular treatment (EVT) should undergo acute carotid stenting, and whether intravenous thrombolysis (IVT) before EVT should influence this decision. We assessed functional and safety outcomes of acute carotid stenting in patients with carotid tandem lesions randomized to IVT plus EVT or EVT alone. METHODS: Individual participant data meta-analysis of 6 randomized clinical trials conducted in Asia, Europe, and Oceania between 2017 and 2021 investigating IVT plus EVT versus EVT alone in patients with carotid tandem lesions presenting directly to EVT-capable centers. The primary outcome was the 90-day modified Rankin Scale score, assessed with mixed-effect ordinal regression models. Safety outcomes were any intracranial hemorrhage and symptomatic intracranial hemorrhage. A secondary analysis used inverse probability of treatment weighting. Treatment effect heterogeneity between IVT plus EVT and EVT alone was assessed in a 2-step meta-analysis. RESULTS: Overall, 340 of 2267 (15%) patients had carotid tandem lesions with 113 of 329 (34%) undergoing acute carotid stenting. Stenting was associated with better 90-day functional outcomes (adjusted common odds ratio, 1.60 [95% CI, 1.03–2.47]), confirmed in inverse probability of treatment weighting analysis (adjusted common odds ratio, 1.66 [95% CI, 1.08–2.54]). Patients undergoing stenting had no statistically significant higher rates of any intracranial hemorrhage (44% versus 35%; adjusted odds ratio, 1.30 [95% CI, 0.79–2.15]) and symptomatic intracranial hemorrhage (6.3% versus 3.7%; adjusted odds ratio, 2.09 [95% CI, 0.78–5.59]). No heterogeneity in treatment effect was observed in patients randomized to IVT plus EVT (adjusted common odds ratio, 2.07 [95% CI, 1.06–4.07]) or EVT alone (1.21 [95% CI, 0.59–2.50]; P interaction=0.81). CONCLUSIONS: In this international individual participant data meta-analysis of patients with carotid tandem lesions randomized to EVT alone or IVT followed by EVT, acute carotid stenting during EVT was associated with better functional outcomes, and this association was not modified by prior treatment with IVT.


  • Correction to: Silk vista baby for the treatment of distal anterior cerebral artery aneurysms

    by Luca Scarcia, Frédéric Clarençon, Adam A. Dmytriw, Eimad Shotar, Pascal Jabbour, Marios Psychogios, Peter Sporns, Ajit S. Puri, Ameer E. Hassan, Oktay Algin, et al.

  • Practical arterial atlas of the pig for neurointerventional simulation

    by Mirella Merlette, Aymeric Rouchaud, Charbel Mounayer, Eimad Shotar, Chrysanthi Papagiannaki, Claude Couquet, Géraud Forestier, Frederic Crampon, Elisabeth Garrido, Emmanuel Gerardin, et al.

    This article presents a practical anatomical atlas of the arterial neuroanatomy of the swine, intended for training and research in neurointerventional surgery. The swine is a well-established large-animal model due to its anatomical similarities with humans. The atlas begins with a concise overview of the femoroiliac arterial tree and the aorta, followed by a focused description of the common carotid and subclavian arteries, and finally the cephalic arteries—both intracranial and extracranial. Average lengths and diameters of the cephalic arterial segments in pigs (30–80 kg) were retrospectively determined from 3D rotational angiographies acquired in five animals previously used in experimental studies. Anatomical descriptions are supported by schematic diagrams and volume rendering reconstructions. This reference tool is designed to standardize anatomical understanding, enhance the effective use of the pig model, and minimize animal distress in experimental procedures. It serves as a valuable resource for practitioners in neurointerventional surgery.


  • Silk Vista Baby for the treatment of distal anterior cerebral artery aneurysms

    by Luca Scarcia, Frédéric Clarençon, Adam A. Dmytriw, Eimad Shotar, Pascal Jabbour, Marios Psychogios, Peter Sporns, Ajit S. Puri, Ameer E. Hassan, Oktay Algin, et al.

    Purpose Treating small-caliber vessel aneurysms with flow diverters poses challenges due to narrow luminal diameters and tortuous vasculature, which complicate the navigation and deployment of conventional devices using standard microcatheters. The Silk Vista Baby (SVB, Balt, Montmorency, France) flow diverter was developed to treat intracranial aneurysms located in smaller vessels or more distal segments and is compatible with 0.017″ microcatheters. We present the largest multicenter analysis to date evaluating the outcomes of SVB use in unruptured distal anterior cerebral artery (DACA) aneurysms. Methods Retrospective data from 20 centers were reviewed for patients with unruptured DACA aneurysms treated with the SVB. Demographic information, clinical presentation, radiographic characteristics, complications, and outcomes were recorded. Results Seventy-nine patients (79 DACA aneurysms) were treated between January 2018 and December 2022; 59 were female (74.7%), and the median age was 61 years (IQR 53–67). Most aneurysms were saccular (89.9%), and 65.8% involved a branch. The median parent vessel diameter was 1.9 mm (IQR 1.7–2.1). A single stent was implanted in 97.5% of cases; 2.5% required two stents. The median imaging follow-up duration was 12 months (IQR 9.5–24). At the last follow-up, 76% of aneurysms showed complete or near-complete occlusion (O’Kelly–Marotta scale C or D, Raymond-Roy 1 or 2). Overall, thromboembolic or hemorrhagic complications occurred in 14% of patients, with two cases being symptomatic. The mortality rate was 0%, and the retreatment rate was 1.3%. Conclusion In this multicenter series, the SVB flow diverter represented a valuable treatment option for distal anterior cerebral artery (DACA) aneurysms.


  • Open Access

    Imaging follow-up of unruptured intracranial aneurysms treated with flow diverter: Insights from a French collaborative survey

    by Thomas Marque, Victor Dumas, Thibault Agripnidis, François Zhu, Guillaume Charbonnier, Baptiste Donnard, Quentin Holay, Jean Darcourt, Luca Scarcia, Alexis Guédon, et al.


  • Flow-diverting stents for the treatment of unruptured distal anterior cerebral artery aneurysms: analysis of the CRETA Registry

    by Luca Scarcia, Frédéric Clarençon, Adam A Dmytriw, Eimad Shotar, Kevin Premat, Pascal Jabbour, Stavropoula I Tjoumakaris, Reid Gooch, Marios-Nikos Psychogios, Nikolaos Ntoulias, et al.

    Background Data about the safety and the efficacy of flow diversion for distal anterior cerebral artery (DACA) aneurysms are limited. We present the largest multicenter analysis evaluating the outcomes of flow diversion in unruptured DACA aneurysm treatment. Methods Databases from 39 centers were retrospectively reviewed for unruptured DACA aneurysms treated with flow-diverting stents. Demographics, clinical presentation, radiographic characteristics, procedural complications, and outcomes were assessed. Results A total of 168 patients with 168 unruptured DACA aneurysms were treated between January 2018 and December 2022. One hundred and twenty-five were women (74.4%) and the median age was 61 (IQR 52–67) years. The most common morphology was saccular (91.7%), with branch involvement in 61.9% of cases. Median parent vessel diameter was 1.9 mm (IQR 1.7–2.2) and stents were successfully deployed in 99.4% of cases. In 96.4% a single stent was implanted, while 3.6% of cases required two stents. Median imaging follow-up was 16.5 (IQR 7–24) months. At last follow-up the rate of occlusion (O’Kelly–Marotta scale C or D) was 82.1%. Symptomatic thromboembolic or hemorrhagic complications occurred in 5.3% of patients and the mortality rate was 0.6%. The rate of retreatment was 1.2%. Conclusions Flow-diverting stents are a reasonably safe and effective treatment option for unruptured DACA aneurysms.


  • Open Access

    CLinical EValuation of WEB 17 device in intracranial aneuRysms (CLEVER): 1-year effectiveness results for ruptured and unruptured aneurysms

    by Laurent Spelle, Vincent Costalat, Jildaz Caroff, Fritz Wodarg, Sebastian Fischer, Denis Herbreteau, Markus A Möhlenbruch, Anne-Christine Januel, Chrysanthi Papagiannaki, Joachim Klisch, et al.

    Background The Woven EndoBridge (WEB) device is designed to treat wide-necked bifurcation aneurysms. The WEB 17 is the latest iteration and can be delivered through a 0.017″ microcatheter. The CLEVER study demonstrated that WEB 17 is safe and effective for providing protection against bleeding or rebleeding at 1 month and 1 year. Objective To evaluate angiographic stability at 1 year. Methods The CLEVER study was a prospective multicenter study conducted in 17 European centers, involved 163 subjects, comprising 60 ruptured and 103 unruptured aneurysms. Independent assessment of 1-year follow-up imaging was incorporated into the study design. Results Aneurysm diameters ranged from 2.0 to 9.2 mm, with 95.7% being broad-based (dome-to-neck ratio Conclusion Delivery of the WEB 17 via 0.017 inch catheters represents a significant evolution of the WEB design. The results of CLEVER presented here demonstrate that it maintains the same efficacy as previous generations of WEB.